Angus Chen is a reporter at STAT. He specializes in medicine and healthcare, with a focus on oncology, hematology, and innovative treatments such as immunotherapy and gene therapy. His work has been featured in publications including RealClearHealth, RamaOnHealthcare, and The Boston Globe.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Angus Chen's focus on healthcare and pharmaceuticals, particularly around cancer treatment and CAR-T therapy, indicates a preference for data-driven insights. He may be more receptive to pitches that offer access to experts who can provide analysis based on hard scientific evidence or clinical research.
Considering Angus's coverage attributes, he would likely appreciate pitches pertaining to significant events in the healthcare and pharmaceutical industry related to cancer treatment advancements or updates in CAR-T therapy. Pitches with information derived from new studies or findings could also prove beneficial when reaching out to him.
As there is no specific geographic focus mentioned for Angus, it is advisable to tailor relevant topics globally as long as they are pertinent within the context of his coverage themes.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Angus Chen, Crystal Milner
Highlights Researchers Alika Maunakea and Ruben Juarez are conducting one of the largest studies on the long-term health effects of wild and urban fire exposure.
W When Stephen Rosenfeld and Patricia Seymour founded the not-for-profit North Star Review Board, they'd become disillusioned with the scientific oversight system in America.
By: Angus Chen
“What was striking was the consistency,” said Tim Donahue, the senior author on the study and a surgical oncologist at the University of California, Los Angeles. “Across every cancer we studied, patients are waiting longer today than they were a decade ago.”
By: Angus Chen, Matthew Herper
Results could herald a new, powerful approach in other cancers A personalized mRNA cancer vaccine, added to an existing treatment, slowed
By: Matthew Herper, Angus Chen
Results could herald a new, powerful approach in other cancers. This story is republished from STAT , the health and medicine news site that's a partner to the Globe.
By: Matthew Herper, Angus Chen, Jason Mast
The drugmakers overcame rampant doubts, logistical challenges, and the pandemic
By: Adam Feuerstein, Angus Chen
The therapy, Rasonque from Revolution Medicines, nearly doubled overall survival in a clinical trial
Is it the ‘secret sauce' in the cancer vaccine co-developed with Merck?
With clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the technology in other areas.
Experts hope the success of a cancer vaccine using the technology can rehabilitate the field
